DFFN VS JAGX Stock Comparison

Performance

DFFN
10/100

DFFN returned -61.80% in the last 12 months. Based on SPY's performance of -8.71%, its performance is below average giving it a score of 10 of 100.

JAGX
10/100

JAGX returned -96.90% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

DFFN
75/100

1 analysts offer 12-month price targets for DFFN. Together, they have an average target of 0, the most optimistic target put DFFN at 0 within 12-months and the most pessimistic has DFFN at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

JAGX
75/100

1 analysts offer 12-month price targets for JAGX. Together, they have an average target of 0, the most optimistic target put JAGX at 0 within 12-months and the most pessimistic has JAGX at 0.

Technicals

DFFN
14/100

DFFN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

JAGX
21/100

JAGX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

DFFN
10/100

DFFN has missed earnings 7 times in the last 20 quarters.

JAGX
10/100

JAGX has missed earnings 12 times in the last 20 quarters.

Profit

DFFN
10/100

Out of the last 20 quarters, DFFN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

JAGX
10/100

Out of the last 20 quarters, JAGX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

DFFN
48/100

DFFN has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

JAGX
54/100

JAGX has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

Sentiment

DFFN

"Sentiment" not found for DFFN

JAGX
70/100

JAGX had a bullish sentiment score of 69.95% across Twitter and StockTwits over the last 12 months. It had an average of 251.11 posts, 260.33 comments, and 684.97 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

DIFFUSION PHARMACEUTICALS INC Summary

Nasdaq / DFFN

Healthcare

Biotechnology

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Jaguar Health, Inc. Summary

Nasdaq / JAGX

Healthcare

Biotechnology

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Power up your portfolio